Progression of fertility-sparing treatment for atypical endometrial hyperplasia in a woman with lynch syndrome: a case report and review of the literature.

Ya-Ting Hsu, Chi-Hau Chen
Author Information
  1. Ya-Ting Hsu: Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
  2. Chi-Hau Chen: Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.

Abstract

endometrial cancer in Lynch syndrome is characterized by a higher incidence, younger age at onset, and increased recurrence rates compared to sporadic cases, while the safety and efficacy of fertility-sparing treatments remain uncertain. This case report presents the oncology outcome of fertility-preserving treatment in a 39-year-old woman diagnosed with Lynch syndrome and atypical endometrial hyperplasia. Initially, she responded favorably to fertility-preserving treatment but subsequently experienced disease relapse and rapid progression during retreatment. Final pathology revealed endometrial cancer with metastasis to the right ovary, categorized as FIGO 2023 stage IIIA1. This population's unique molecular mechanisms and genetic mutations warrant special consideration when opting for fertility-sparing treatment. We have reviewed and summarized the oncology and pregnancy outcomes among Lynch syndrome and MMR-deficient patients through previous literature. However, no studies have investigated retreatment after recurrence in Lynch syndrome. Our case highlights the potential risks associated with retreatment following relapse. Vigilant monitoring and prompt consideration of surgical intervention are recommended upon disease relapse.

Keywords

References

  1. Cancers (Basel). 2021 Jun 07;13(11): [PMID: 34200374]
  2. Int J Gynecol Cancer. 2018 Feb;28(2):385-393 [PMID: 29266019]
  3. Front Med (Lausanne). 2022 Aug 25;9:948509 [PMID: 36091691]
  4. Cancer Res. 2006 Aug 1;66(15):7810-7 [PMID: 16885385]
  5. Obstet Gynecol. 2005 Mar;105(3):569-74 [PMID: 15738026]
  6. Front Oncol. 2021 Sep 09;11:738370 [PMID: 34568074]
  7. Cancers (Basel). 2021 May 26;13(11): [PMID: 34073635]
  8. Gut. 2018 Jul;67(7):1306-1316 [PMID: 28754778]
  9. Gynecol Oncol. 2021 Jun;161(3):795-801 [PMID: 33812697]
  10. Int J Clin Oncol. 2019 Jun;24(6):712-720 [PMID: 30746595]
  11. Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:220-225 [PMID: 31326637]
  12. Am J Obstet Gynecol. 2021 Apr;224(4):370.e1-370.e13 [PMID: 33039397]
  13. Fam Cancer. 2013 Jun;12(2):273-7 [PMID: 23765559]
  14. BJOG. 2017 Sep;124(10):1576-1583 [PMID: 28128512]
  15. Cancer Control. 2009 Jan;16(1):14-22 [PMID: 19078925]
  16. Gynecol Oncol. 2023 Dec;179:180-187 [PMID: 37992549]
  17. Gynecol Oncol. 2012 May;125(2):477-82 [PMID: 22245711]
  18. Am J Obstet Gynecol. 2012 Oct;207(4):266.e1-12 [PMID: 23021687]

Word Cloud

Created with Highcharts 10.0.0syndrometreatmentendometrialLynchfertility-sparingcancercaseoncologyatypicalhyperplasiarelapseretreatmentrecurrencereportoutcomefertility-preservingwomandiseaseconsiderationliteraturelynchEndometrialcharacterizedhigherincidenceyoungerageonsetincreasedratescomparedsporadiccasessafetyefficacytreatmentsremainuncertainpresents39-year-olddiagnosedInitiallyrespondedfavorablysubsequentlyexperiencedrapidprogressionFinalpathologyrevealedmetastasisrightovarycategorizedFIGO2023stageIIIA1population'suniquemolecularmechanismsgeneticmutationswarrantspecialoptingreviewedsummarizedpregnancyoutcomesamongMMR-deficientpatientspreviousHoweverstudiesinvestigatedhighlightspotentialrisksassociatedfollowingVigilantmonitoringpromptsurgicalinterventionrecommendeduponProgressionsyndrome:review

Similar Articles

Cited By

No available data.